BREAST CANCER AOTEAROA COALITION INC

PERFORMANCE REPORT

FOR THE YEAR ENDED 31ST MARCH 2026

CONTENTS **PAGE**

Non-Financial Information:

Entity Information.....3

Statement of Service Performance.....5

Financial Information:

Statement of Financial Performance.....8

Statement of Financial Position.....9

Statement of Cash Flows.....11

Statement of Accounting Policies..... 12

Notes to the Performance Report.....13

Approval of Performance Report 15

Audit Report.....16

Breast Cancer Aotearoa Coalition Incorporated

Certificate of Incorporation: 1897085

Certificate of Registration as a Charitable Entity: CC22456

IRD/Exemption Number: 95-344-461

Breast Cancer Aotearoa Coalition Inc

Entity Information

For the Year Ended 31st March 2026

Legal Name: Breast Cancer Aotearoa Coalition Incorporated
Other Name: BCAC
Type of Entity and Legal Basis: An incorporated society established under the Incorporated Societies Act 1908 and registered as a Charity on 3 April 2008.
Certificate of Incorporation: 1897085
IRD/Exemption Number: 95-344-461
NZBN: 9429043170364
Registration Number: CC22456

Mission
To make world-class detection, treatment and care accessible to all those affected by breast cancer in Aotearoa, New Zealand.

To provide information and support to empower those with breast cancer to make informed choices about their treatment and care.

To provide a voice for New Zealanders who have experienced breast cancer.

Structure
The BCAC is a stand alone entity.

Governance arrangements
The BCAC has a Managing Committee comprising: Chairperson, Deputy Chairperson, Secretary, Treasurer and further members as decided by the Society. Only Members of the BCAC may be Committee Members. Committee Members are appointed by majority vote at a General Meeting. There is no fixed term for Committee membership. If the position of any Committee Member becomes vacant between General Meetings, the Committee may appoint another Committee Member to fill that vacancy until the next General Meeting. The BCAC operates according to a formal Constitution.

Relationships to other entities
There are no other entities controlled by the BCAC.

The BCAC operates as an umbrella organisation, representing and providing support and information to individuals and groups with an interest in improving outcomes for New Zealanders experiencing breast cancer. The BCAC has a coordinating role, facilitating communication and cooperation among its member groups.

Reliance on volunteers and donated goods or services
The BCAC relies on gifts of volunteer time and expertise to administer the Society and to carry out its purposes, e.g. researching current evidence-based information about breast cancer detection, treatment and care and promoting and supporting such research; providing support to New Zealanders experiencing breast cancer by distributing a free informative support pack; maintaining a website with evidence-based relevant information, advice and news; distributing a regular free electronic newsletter; posting relevant news on BCAC's Facebook page; running an

online peer support group for those experiencing breast cancer; promoting the activities of its 30 breast cancer-related member groups; helping individuals in difficulty to connect with appropriate service providers; representing those affected by breast cancer in Aotearoa New Zealand to parliament, the health system, the scientific and medical communities, media, corporate entities and the general public; providing consumer input and representation at regional and national levels to the development of policies and strategies affecting those with breast cancer in Aotearoa New Zealand; and facilitating connections and networks of people and organisations sharing similar issues, concerns and experiences in relation to breast cancer.

The BCAC does not rely on donated goods or services.

Membership
BCAC Members may be Ordinary, Corporate or Life Members. Individuals and groups, including other registered charities, interested achieving the BCAC's mission make up the membership. A register of members is kept and is reported at the BCAC's Annual General Meeting.

Main sources of cash and resources
The BCAC's activities are funded by donations and grants from individuals, businesses, other charities, NGOs and government entities, bequests and interest on savings.

Main methods used to raise funds
This year BCAC continued to receive regular donations from the public, often in memory of women who had been significant supporters of BCAC's work. BCAC received some public donations via The Good Registry charity, which issues gift certificates for donors. A direct bequest was also received. An educational grant from pharmaceutical company Merck Sharpe and Dohme supported two Committee members' travel to Breast Cancer Trials' Annual Scientific Meeting, an international breast cancer research conference held in Hobart, Australia. Interest from term deposit investments also contributed to BCAC's revenue this year. BCAC does not use a third party to raise funds. It does not charge a fee for membership and it does not require payment for the goods and services it supplies.

Additional information
Further information may be obtained from www.breastcancer.org.nz

Contact details
Postal Address: PO Box 90224, Auckland Mail Centre, Victoria Street West, Auckland 1142

Email: bcac@breastcancer.org.nz

Facebook: https://www.facebook.com/BreastCancerAotearoaCoalition

Breast Cancer Aotearoa Coalition Inc

Statement of Service Performance

For the Year Ended 31st March 2026

Medium to long term objectives

- Inform and support those diagnosed with breast cancer by providing evidence-based information to help them and their families make informed decisions about their treatment and care.
- Represent the views of women with breast cancer to clinicians, health officials, regulators, policymakers and other relevant decision-makers to ensure world-class detection, treatment and care is available in New Zealand.
- Promote breast awareness for women of all ages and regular breast screening from age 40 onwards.
- Advocate for improvements in breast cancer risk assessment and screening.
- Advocate for better access to modern medicines and other treatments for early and metastatic breast cancer.
- Improve breast cancer outcomes for Māori and Pasifika women by consulting and engaging with these communities.
- Network to ensure communication and sharing of resources and information among breast cancer-related groups and organisations.

Key activities

Activity 1. Make world class detection, treatment and care accessible to all those affected by breast cancer in Aotearoa New Zealand:

- Continue engagement with decision makers at all levels
- Continue to update our knowledge of effective treatments through interaction with medical experts and attendance at research meetings
- Support the establishment and implementation of Quality Performance Indicators for breast cancer
- Support the development and implementation of NZ Guidelines for Advanced Breast Cancer
- Raise awareness of new and emerging medicines and the need for increased medicines funding
- Meet with Pharmac to champion access to new and innovative medicines proven to deliver results
- Meet with pharmaceutical companies and encourage them to import and register their innovative medicines in New Zealand, apply for Pharmac funding and offer them at affordable prices in cost-share patient access programmes and free of charge to patients when funding is imminent
- Continually review the performance of the Cancer Control Agency Te Aho o Te Kahu and provide patient-focused input

- Advocate for new ways that breast cancer care can be provided to improve outcomes
- Consult, engage with, empower and, when appropriate, represent Māori and Pasifika women on breast issues and advocate for actions needed to increase access to services, and improve breast cancer experiences and outcomes
- Increase education and knowledge of breast cancer, treatments, supportive care and emerging clinical trial results by attending and promoting local and international expert meetings and conferences
- Advocate for the establishment of schemes enabling early and broader medicines access
- Encourage the adoption of genetic and genomic testing in the treatment of breast cancer in NZ. Such tests can identify those at higher-than-average risk of getting breast cancer, so that they can be more vigilant or take preventative measures (such as surgery) to lower their risk, and can also be used in those already diagnosed with breast cancer to identify tumour sub-types more precisely and to assess risk of recurrence. This information helps clinicians to tailor treatments for optimal outcomes.
- Engage and network with the key stakeholders across the health system to encourage and support consumer, Māori, and Pacific involvement and participation in breast cancer clinical research and its translation by partnering at a governance, local/regional level
- Continue networking and collaboration among groups and individuals.

(Quantitative measure: number of relevant meetings attended by Committee Members)

Activity 2. To provide information and support to empower those with breast cancer to make informed choices about their treatment and care:

- Widely distribute *Step by Step* to women newly diagnosed with breast cancer throughout NZ
- Provide information and support for those with early and advanced breast cancer
- Provide up to date information via our website about breast cancer and our advocacy work
- Communicate with the breast cancer community via our Facebook page and group
- Continue to support the Metavivors NZ and Metavivors NZ – Action Facebook groups
- Distribute news and information via our e-newsletter to hundreds of subscribers
- Share findings of breast cancer research through our website and social media
- Respond to requests for information and support.

(Quantitative measure: number of Step by Step packs distributed)

Activity 3. To provide a unified evidence-based voice for New Zealanders who have experienced breast cancer:

- Advocate for timely access to world-class breast care, including treatments and supportive care in New Zealand
- Raise awareness of advanced breast cancer and related needs for support and services

- Actively participate in a wide range of local, regional and national and international breast cancer-related working groups, panels, committees, organisations and conferences
- Respond to consultation opportunities relating to breast cancer
- Provide a public voice through ongoing liaison with media, interviews and media releases
- Support and promote initiatives enabling the early detection of breast cancer such as mammographic screening, breast density reporting and breast awareness by meeting regularly with BreastScreen Aotearoa to encourage continual progress with the national breast screening programme, including broadening the eligible age band and ensuring the backlog of screening caused by Covid-19 related issues is adequately addressed
- Provide information and comment on the most effective ways to achieve early detection.

(Quantitative measure: number of relevant events in which BCAC Committee Members participated)

Activity 4. To support the activities of BCAC through promotion and fundraising:

- Apply for grants from charitable trusts
- Approach businesses for funding to support specific projects and activities
- Welcome public donations via our website, social media posts and newsletters.

(Quantitative measure: number of relevant events in which BCAC Committee Members participated)

Quantification of Key Activities	**Actual 2025/26**	**Actual 2024/25**
1. Number of meetings attended with the goal of bringing world class care to NZers with breast cancer	36	50
2. Number of Step by Step support packs delivered to New Zealanders newly-diagnosed with breast cancer	1,317	1,451
3. Number of meetings attended with the primary goal of representing NZers with breast cancer	37	47
4. Number of fundraising events attended	0	0

Breast Cancer Aotearoa Coalition Inc

Statement of Financial Performance

For the Year Ended 31st March 2026

	Actual 2026	Actual 2025
Revenue		
Donations, koha, bequests and other general fundraising activities	$ 25,382	$158,512
General grants (educational, Lotteries Commission, etc.)	$ 8,315	$ 1,434
	$ -	$ -
Revenue from commercial activities	$ -	$ -
Interest, dividends and other investment revenue	$ 30,418	$ 26,648
Total revenue	$ 64,115	$186,594
Expenses		
Expenses related to public fundraising	$ -	$ -
Employee remuneration and other related expenses	$ -	$ -
Volunteer related expenses	$ 21,537	$ 5,899
Expenses related to delivering services	$ 10,928	$ 13,459
Other expenses related to service delivery	$ 7,201	$ 2,786
Value of support packs delivered	$ 21,270	$ 23,437
Other expenses	$ -	$ -
Total expenses	$ 60,936	$ 45,581
Surplus/Deficit for the Year	$ 3,179	$141,013

These Notes form part of this Performance Report and should be read in conjunction with the Audit Report

Forbes Audit Auckland

Breast Cancer Aotearoa Coalition Inc

Statement of Financial Position

As at 31st March 2026

	Actual 2026	Actual 2025
Assets		
Current Assets		
Cash and short-term deposits	$ 43,780	$ 45,025
Debtors and prepayments	$ 5,032	$ 302
Inventory	$ 34,916	$ 56,186
Other current assets	$ -	$ 4,719
Total Current Assets	$ 83,729	$ 106,232
Non-Current Assets		
Property, plant and equipment	$ -	$ -
Investments	$ 649,355	$ 619,438
Other non-current assets	$ -	$ -
Total Non-Current Assets	$ 649,355	$ 619,438
Total Assets	$ 733,084	$ 725,670
Liabilities		
Current Liabilities		
Bank overdraft	$ -	$ -
Creditors and accrued expenses	$ 4,263	$ 29
Employee costs payable	$ -	$ -
Deferred revenue	$ -	$ -
Other current liabilities	$ -	$ -
Total Current Liabilities	$ 4,263	$ 29
Non-Current Liabilities		
Loans	$ -	$ -
Total Non-Current Liabilities	$ -	$ -
Total Liabilities	$ 4,263	$ 29
Total Assets less Total Liabilities (Net Assets)	$ 728,820	$ 725,641

These Notes form part of this Performance Report and should be read in conjunction with the Audit Report

Forbes Audit Auckland

Accumulated Funds	Actual 2026	Actual 2025
Capital contributed by owners or members	$ -	$ -
Accumulated surpluses or (deficits) open balance	$ 725,641	$ 584,628
Net surplus/(deficit) for the year	$ 3,179	$ 141,013
Total accumulated surpluses/(deficits) at 31.3.26	$ 728,820	$ 725,641
Reserves		
Total Accumulated Funds	$ 728,820	$ 725,641

Forbes Audit Auckland

Breast Cancer Aotearoa Coalition Inc

Statement of Cash Flows

For the Year Ended 31st March 2026

	Actual 2026	Actual 2025
Cash Flows from Operating Activities		
Operating receipts:		
Donations, koha, bequests and other general fundraising activities	$ 25,382	$ 158,512
General grants	$ 8,315	$ 1,434
Membership fees and subscriptions	$ -	$ -
Interest, dividend and other investment receipts	$ 30,320	$ 21,929
Other cash received (net GST, repaid debt)	$ 135	$ 3,729
Total receipts	$ 64,152	$ 185,604
Less operating payments:		
Payments related to service delivery	$ 13,942	$ 16,259
Employee remuneration and payments	$ -	$ -
Volunteer related payments	$ 21,537	$ 5,899
Total payments	$ 35,479	$ 22,158
Net Cash Flows from Operating Activities	$ 28,673	$ 163,446
Cash Flows from Other Activities		
Cash was received from:		
Sale of property, plant and equipment	$ -	$ -
Sale of investments	$ -	$ -
Cash received from loans borrowed from other parties	$ -	$ -
Capital received from owners (capital contributions)	$ -	$ -
Cash was applied to:		
Payments to acquire property, plant and equipment	$ -	$ -
Movement in investments	$ (29,918)	$ (169,625)
Repayments of loans borrowed from other parties	$ -	$ -
Capital repaid to owners	$ -	$ -
Net Cash Flows from Other Activities	$ (29,918)	$ (169,625)
Net Increase/Decrease in Cash	$ (1,245)	$ (6,179)
Opening Cash	$ 45,025	$ 51,204
Closing Cash	$ 43,780	$ 45,025
This is represented by bank accounts and cash:	$ 43,780	$ 45,025

These Notes form part of this Performance Report and should be read in conjunction with the Audit Report

Forbes Audit Auckland

Breast Cancer Aotearoa Coalition Inc

Statement of Accounting Policies

For the Year Ended 31st March 2026

Basis of Preparation
This performance report is prepared in accordance with the XRB's Tier 3 (NFP) Standard. The entity is eligible to apply these requirements as it does not have public accountability and has total annual expenses of less than $5,000,000. All transactions in the performance report are reported using the accrual basis of accounting. This performance report is prepared under the assumption that the entity will continue to operate for the foreseeable future.

Treatment of Goods and Services Tax (GST)
The Breast Cancer Aotearoa Coalition Inc. is registered for GST (no. 95-344-461). All amounts are recorded exclusive of GST, except for Debtors and Creditors which are stated inclusive of GST.

Income Tax
The Breast Cancer Aotearoa Coalition Inc. is wholly exempt from New Zealand income tax having fully complied with all statutory conditions for these exemptions.

Bank Accounts and Cash
Cash and short term deposits in the Statement of Cash Flows comprise cash balances and bank balances (including short term deposits) with original maturities of 90 days or less.

Tier 2 PBE Accounting Standards Applied (if any)
None.

Changes in Accounting Policies
There have been no changes in accounting policies during the financial year (last year nil).

Audit
These financial statements have been subject to audit, please refer to Auditor's Report.

Inventory
Inventory is made up of 2162 copies of Step by Step valued at $16.15 a copy. As copies are distributed, they are removed from inventory and expensed.

Forbes Audit Auckland

Breast Cancer Aotearoa Coalition Inc

Notes to the Performance Report

For the Year Ended 31st March 2026

Grants and Donations with Documented Expectations
None.

Goods or Services in Kind Provided to the Entity
None.

Property, Plant and Equipment
None.

Significant Donated Assets Not Recorded
None.

Significant Heritage Assets Not Recorded
None.

Assets Used as Security for Liabilities
None.

Assets Held on Behalf of Others
None.

Changes in Accumulated Funds
There has been no capital contributed by owners or members. There are no reserves. Changes in the accumulated funds are accounted for in the Statements of Financial Performance, Financial Position and Cash Flows.

Commitments
There are no capital commitments at balance date (2025:$0).

Contingent Liabilities
At balance date there are no known contingent liabilities (2025:$0). The Breast Cancer Aotearoa Coalition Inc. has not granted any securities in respect of liabilities payable by any other party whatsoever.

Related Party Transactions
There have been no related party transactions (2025:$0).

Events After the Balance Date
There have been no significant events after the balance date that would have a material impact on the Performance Report (2025:$0).

Ability to Continue Operating
The Management Committee considers that it has sufficient resources to continue to operate and considers that the presentation of the performance report on a going concern basis is still appropriate. The Breast Cancer Aotearoa Coalition Inc. does not intend to stop operating within 12 months from the balance date.

Forbes Audit Auckland

Breast Cancer Aotearoa Coalition Inc

Notes to the Performance Report

For the Year Ended 31st March 2026

Correction of Errors

None.

Additional Information

None.

List of Donors and Grants

Bequest from Patricia Henderson	$ 20,000
Public donations	$ 5,382
Educational grant	$ 8,315

Forbes Audit Auckland

Breast Cancer Aotearoa Coalition Inc

Approval of Performance Report

For the Year Ended 31st March 2026

The Managing Committee approves the Performance Report on pages 1-14 for the year ended 31 March 2026 for the Breast Cancer Aotearoa Coalition Inc.

For and on behalf of the Managing Committee:



Chairperson



Treasurer

Date: 21 09 2026

FORBES audit professionals

INDEPENDENT AUDITOR'S REPORT

To the Director of Breast Cancer Aotearoa Coalition Inc

Opinion

We have audited the financial information in the Performance Report of Breast Cancer Aotearoa Coalition Inc on pages 8 to 14, which comprise the Statement of Financial Position as at 31 March 2026, and the Statement of Financial Performance and Statement of Cash Flows for the year then ended, a Statement of Accounting Policies and Notes to the Performance Report including material accounting policy information and other explanatory information. We were not engaged to audit the Entity Information or Statement of Service Performance and accordingly these statements, representing other information, are not included in our audit.

In our opinion, the financial information in the accompanying Performance Report presents fairly, in all material respects, the financial position of Breast Cancer Aotearoa Coalition Inc as at 31 March 2026, and its financial performance and its cash flows for the year then ended in accordance with the requirements of the Tier 3 (NFP) Standard issued by the New Zealand Accounting Standards Board of the External Reporting Board (XRB).

Basis for Opinion

We conducted our audit in accordance with International Standards on Auditing (New Zealand) (ISAs (NZ)). Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Performance Report section of our report. We are independent of Breast Cancer Aotearoa Coalition Inc in accordance with Professional and Ethical Standard 1 'International Code of Ethics for Assurance Practitioners (including International Independence Standards) (New Zealand), and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Other than in our capacity as auditor we have no relationship with, or interests in, Breast Cancer Aotearoa Coalition Inc.

Other Information: Entity Information and Statement of Service Performance

The Director is responsible for the other information. The other information comprises the Entity Information and Statement of Service Performance but does not include the Performance Report and our auditor's report thereon.

In connection with our audit of the Performance Report, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the Performance Report or our knowledge obtained in the audit or otherwise appears to be materially misstated. If, based on the work we have performed, we

conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Director' Responsibility for the Performance Report

The Director is responsible on behalf of the entity for determining that the Tier 3 (NFP) Standard is acceptable in the entity's circumstances and, for:
(a) the selection of elements/aspects of service performance, performance measures and/or descriptions and measurement bases or evaluation methods that present service performance information that is appropriate and meaningful in accordance with the Tier 3 (NFP) Standard;
(b) the preparation and fair presentation of the Performance Report which comprises:

- the Entity Information;
- the Statement of Service Performance; and
- the Statement of Financial Performance, Statement of Financial Position, Statement of Cash Flows, Statement of Accounting Policies and Notes to the Performance Report in accordance with the Tier 3 (NFP) Standard, and

(c) for such internal control as the Director determine is necessary to enable the preparation of a Performance Report that is free from material misstatement, whether due to fraud or error.

In preparing the Performance Report, the Director is responsible on behalf of the entity for assessing the entity's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Director either intend to liquidate the entity or to cease operations, or have no realistic alternative but to do so.

Auditor's Responsibilities for the Audit of the Financial Information in the Performance Report

Our objectives are to obtain reasonable assurance about whether the financial information in the Performance Report is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with ISAs (NZ) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the decisions of users taken on the basis of this Performance Report.

As part of an audit in accordance with ISAs (NZ), we exercise professional judgement and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial information in the Performance Report, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and

appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of the use of the going concern basis of accounting by the Director and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the entity's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial information in Performance Report or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the entity to cease to continue as a going concern.

We communicate with the Director regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Other Matter

The comparative information for the year ended 31 March 2025 was audited by another auditor, whose report dated 3 August 2025 expressed an unmodified opinion on that Performance Report. We were appointed as auditor for the year ended 31 March 2026 and, accordingly, do not express an opinion or any other form of assurance on the comparative information. Our opinion is expressed solely on the Performance Report for the year ended 31 March 2026.

Forbes

Forbes Audit Limited
Auckland
23 September 2026